Anastasiia Shvyrkova
Research Subjects
Anastasiia Shvyrkova has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- A. Oneill
Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts
17 shared publications - A. Tkachuk
Endocrinology Research Centre
17 shared publications - Aleksandr Sarachakov
BostonGene Corporation, Waltham, MA; The Center for Molecular and Cellular Biology, Moscow, Russia
17 shared publications - B. U. Shanthappa
Boston Gene Corporation, Waltham, Massachusetts
17 shared publications - Glenn J. Hanna
Dana-Farber Cancer Institute 1 Department of Medical Oncology Boston, Massachusetts
17 shared publications - Jochen K. Lennerz
BostonGene, Waltham, USA
17 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Springer Nature in Blood Cancer Journal
Evaluation of gene expression assays to classify large B-cell lymphoma by molecular subtype using formalin-fixed paraffin-embedded tumor biopsies
- 19 October 2026
- Published by Springer Nature in Blood Cancer Journal
Open AccessEvaluation of gene expression assays to classify large B-cell lymphoma by molecular subtype using formalin-fixed paraffin-embedded tumor biopsies
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 2. Representativeness of Study Participants.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 2. Representativeness of Study Participants.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 6 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 6. Results of multiplex immunofluorescence profiling on tumor specimens.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 6 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 6. Results of multiplex immunofluorescence profiling on tumor specimens.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 7 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 7. Correlating pre-treatment tumor immune cell parameters with outcomes (N=18).
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 7 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 7. Correlating pre-treatment tumor immune cell parameters with outcomes (N=18).
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 1. Overview of the multiplex immunofluorescence panel.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 1. Overview of the multiplex immunofluorescence panel.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 5. Univariate Hazard ratio and 95% CI for Cox proportional hazard models on overall survival.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 5. Univariate Hazard ratio and 95% CI for Cox proportional hazard models on overall survival.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 4 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 4. Univariate odds ratio and 95% CI for logistic regression models for predictors of response.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 4 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 4. Univariate odds ratio and 95% CI for logistic regression models for predictors of response.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 3. Reasons for Treatment Discontinuation.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 3. Reasons for Treatment Discontinuation.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 5 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 5. Univariate Hazard ratio and 95% CI for Cox proportional hazard models on overall survival.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 5 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 5. Univariate Hazard ratio and 95% CI for Cox proportional hazard models on overall survival.
- Open Access
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 1. Overview of the multiplex immunofluorescence panel.
- 17 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Duvelisib with Docetaxel for Patients with Anti–PD-1 Refractory, Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma
Supplemental Table 1. Overview of the multiplex immunofluorescence panel.